BAYER AG NA O.N.
Commented by André Will-Laudien on July 1st, 2026 | 06:50 CEST
Here We Go: A Breakthrough for Bayer, Buy Signals for MustGrow and Kraft Heinz
Created and Published on Behalf of MustGrow Biologics Corp.
According to United Nations projections, the world's population is expected to grow to around 9.7 billion people by 2050. The Food and Agriculture Organization (FAO) estimates that this growth can only be managed with significantly more productive and, at the same time, more sustainable farming methods. This is where MustGrow Biologics comes in with biological crop solutions based on natural mustard extracts. And the company's growth story is only just beginning. The sector is gaining short-term momentum now that Bayer has finally received a positive ruling from the US Supreme Court regarding glyphosate. This should allow the Leverkusen-based company's Crop Science division to really take off. At the same time, a powerful structural trend is reshaping the entire agricultural value chain. Natural resources and food must be produced more sustainably and with greater resilience to meet the nutritional needs of a rapidly growing global population. Companies such as Kraft Heinz are responding by leveraging decades of expertise in building resilient agricultural supply chains and climate-adaptive farming systems. These are exciting developments in a sector that is often overlooked in the shadow of high-tech and defence. But the technological trends have long since shifted!
Read
Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST
AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly
Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.
Read
Commented by Matthias Schomber on June 29th, 2026 | 06:45 CEST
Soaring Stock Prices, a Billion-Dollar Ruling, and the Green Transition: The Big Return Showdown Between Lufthansa, Bayer, and A.H.T. Syngas
Sometimes, a single court ruling is enough to fundamentally alter the outlook for a listed company. Bayer demonstrated this vividly this week. Meanwhile, Lufthansa is climbing to new annual highs, supported by falling oil prices and a surprisingly stable credit rating. Then there is A.H.T. Syngas, a small but ambitious provider of biomass power plants that has either just emerged from a consolidation phase, or may be approaching the end of one. Three very different companies, three distinct stages of development—yet all three are worth a closer look at this moment. If you want to understand where opportunities may lie and where caution is warranted, read on.
Read
Commented by Carsten Mainitz on June 25th, 2026 | 07:40 CEST
A Strong Duo in a Huge and Overlooked Growth Market: MustGrow Biologics and Bayer—When Will BayWa Recover?
Created and Published on Behalf of MustGrow Biologics Corp.
Global agriculture is undergoing a profound structural transformation. Climate change—marked by heat waves, droughts, and extreme weather events—is causing billions in crop losses annually in Europe alone. This is driving rising demand for more resilient farming systems and hardier crops. Regenerative agriculture and biological crop protection products are gaining strong momentum, forming the basis of emerging megatrends. According to expert estimates, the market for regenerative agriculture is expected to grow to around USD 50 billion by 2033. This is where the Canadian company MustGrow has positioned itself. Of particular importance is its licensing and development partnership with Bayer for biological crop protection solutions, which creates significant opportunities for this small-cap North American company.
Read
Commented by Armin Schulz on June 24th, 2026 | 08:30 CEST
Cancer remains the hottest bet in the pharmaceutical market: Bayer, Vidac Pharma, and Pfizer are competing for the next generation of therapies
The oncology market is the most dynamic segment of the pharmaceutical industry. While global heavyweights are positioning their multibillion-dollar pipelines, a small biotech company is banking on a scientific approach that directly targets the metabolism of tumour cells. For investors, the key question is whether the future of cancer treatment will be defined by broad-based therapies, targeted antibody-drug conjugates, or precise interventions at the cellular metabolic level. The differing approaches taken by Bayer, Vidac Pharma, and Pfizer promise to set the course not only medically but also financially for the coming decade.
Read
Commented by Nico Popp on June 19th, 2026 | 07:35 CEST
How MustGrow Biologics Benefits from Agrochemical Realignment with Patented Bioactive Technology – Pressure on Bayer and Corteva
Created and published on behalf of MustGrow Biologics Corp.
Extreme heat waves, increasingly degraded soils, and strict regulatory limits on synthetic chemical crop protection products—global agricultural markets are facing a critical period of adjustment. Once temperatures cross the critical threshold of 30 °C, most agricultural crops begin to suffer drastic yield losses, as sterile pollen and weakened cell walls cause irreparable damage to plant biology. According to the joint report by the Food and Agriculture Organization of the United Nations (FAO) and the World Meteorological Organization (WMO) titled "Extreme Heat and Agriculture," even individual heat waves can cause agricultural productivity to plummet by up to 50%. For most major crops, yield losses are already a threat at temperatures as low as 30 °C. The frequency, intensity, and duration of extreme heat events have increased significantly over the past 50 years. These ecological stressors are shifting growing conditions in both temperate and Mediterranean zones, forcing the entire agricultural value chain to rethink its approach.
Read
Commented by André Will-Laudien on June 16th, 2026 | 07:25 CEST
USA–Iran: The Strait of Hormuz is Opening Up! A Sector Buy Signal for Bayer, MustGrow, BASF and K+S!
Created and published on behalf of MustGrow Biologics Corp.
Some things are ultimately not surprising. The "agreement" between the USA–Israel and Iran resembles shadow boxing. One step forward, one step back—that is how the movements at the trading desk appear. The stock markets are reacting accordingly. At the start of the week, optimism about a near-term end to the hostilities is once again dominating. Oil prices are correcting most sharply, down nearly 5%, with Brent now quoted at only USD 82.50 per barrel. This is a positive signal for chemical- and transport-oriented industries in the food sector, with BASF and Bayer showing corresponding strength. Large volumes of goods must be transported globally, and shipping routes carry significant operational importance. As part of efforts to ensure long-term food security, more and more ideas are emerging that could mitigate the international energy crisis. MustGrow focuses on natural ingredients rather than chemicals, while K+S represents a typical example of the "old economy" in this sector. For investors, multiple opportunities for returns are available!
Read
Commented by Armin Schulz on June 11th, 2026 | 06:45 CEST
With Novo Nordisk, MustGrow Biologics, and Bayer: Positioning for Two Megatrends of the Decade
Created and published on behalf of MustGrow Biologics Corp.
Two seemingly opposing crises—obesity and food scarcity—are creating major investment opportunities this year. While the obesity epidemic is placing increasing strain on healthcare systems, climate shocks and geopolitical conflicts are threatening global agricultural yields. The biotech sector is addressing both challenges through biological compounds for weight management and crop protection. Demand for effective obesity treatments and sustainable agricultural solutions is rising rapidly. Investors who position themselves early in the beneficiaries of this dual transformation may benefit from above-average returns. This is precisely where the three companies we are taking a closer look at today are positioned: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Matthias Schomber on June 5th, 2026 | 07:00 CEST
Global Food Security Meets Agritech Innovation: New Developments from Bayer, Nutrien, and MustGrow Biologics
Created and published on behalf of MustGrow Biologics Corp.
Global hunger has been rising dramatically for years and already affects over 750 million people worldwide. Geopolitical conflicts such as the war in Ukraine, the pandemic's aftermath, and intensifying droughts driven by the climate crisis are exposing the extreme vulnerability of our global food supply. To permanently reverse this dangerous trend, development organizations like Bread for the World are calling for a profound, ecological transformation away from pure agribusiness toward sustainable, resilient systems. In this context, agribusiness conglomerates and innovative pioneer companies are under significant pressure to deliver effective solutions quickly. But how are established industry leaders responding to these historic challenges, and what role do innovative organic approaches play in this future market worth hundreds of billions? A look at current market trends reveals where the momentum for a new era in agriculture is building.
Read
Commented by André Will-Laudien on June 2nd, 2026 | 06:55 CEST
Stock Market Rotation Beyond AI: Opportunities in MustGrow, Bayer, and Novo Nordisk; Caution with K+S
Created and published on behalf of MustGrow Biologics Corp.
A shift in perspective remains the order of the day. Yesterday, the ECB met to discuss the current situation regarding inflation and interest rates. With an inflation rate of over 3% in Europe, there is likely no room for downward interest rate adjustments—quite the opposite! The 10-year yield on German government bonds has settled near the 3% mark over the past four weeks, while in the US, the 30-year yield is already above 5%. In the past, these were warning signs for a currently well-valued NASDAQ, as the so-called trailing P/E ratio has soared from 28 to 36. Growth companies, mostly financed through equity, thrive on tech euphoria, whereas capital-intensive industries, such as the life sciences sector, face a different situation. For example, Bayer and Novo Nordisk do not require market financing, as they hold large cash reserves. In the case of K+S, the ability to pass on prices to end customers could lead to rising cash flows, while the Canadian company MustGrow has only recently raised funds and is steadily continuing its rollout in the US. Mid-term investors should focus on sector rotation when tech momentum fades. The chances of a revival in neglected sectors look strong!
Read